• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Primary Care
CMECNE

Asthma: The Stepwise Approach to Treatment

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the recommended treatment strategy for the management of asthma
2. Describe the recommended approach to monitoring patients with asthma

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/01/2022 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

Table of Contents

  • Reducing Impairment
  • Reducing Risk
  • Treatment
  • Managing Acute Exacerbations
  • Monitoring

CLINICAL ACTIONS:

Because asthma is an inherently variable condition, therapy should be reassessed at each visit. Management is a dynamic process that will change based on the patient’s needs over time. 

  • Effective asthma management requires a proactive, preventative and stepwise approach 
  • Control of asthma is viewed in the context of impairment and risk

Reducing Impairment

Optimize care by focusing on the following

  • Symptom prevention: Minimize troublesome coughing or breathlessness in the daytime, during the night, or after exertion
  • Infrequent use of quick-acting inhaled beta-2-selective adrenergic agonists (SABAs): ≤2days a week for quick relief of symptoms
  • Maintain (near) normal pulmonary function
  • Maintain normal activity levels including
    • Exercise and other physical activity
    • Attendance at work or school

Reducing Risk

Use ASTHMA ACTION PLAN (see ‘Learn More – Primary Sources’ below) or other management plan to

  • Prevent recurrent exacerbations
  • Minimize the need for ED visits or hospitalizations
  • Prevent progressive loss of lung function
  • Provide optimal pharmacotherapy with minimal or no adverse effects

SYNOPSIS:

The Expert Panel recommendations specify that treatment must be individualized in a ‘stepwise’ fashion. The guidelines note that “The stepwise approach is meant to help, not replace, the clinical decision making needed to meet individual patient needs.” If a patient remains stable for at 3 months, reducing medications in a ‘step down’ approach can be used. In addition, two key factors to a successful outcome are patient education and measures to control environmental triggers and comorbidities.

KEY POINTS:

Treatment

Intermittent Asthma

Step 1

  • Recommendation: SABAs taken as needed for relief of symptoms
    • Daily scheduled chronic use of SABA is not recommended
  • If SABA >2 days a week for symptom relief: Inadequate control and consider next category (mild persistent asthma) and use of anti-inflammatory therapy
  • SABAs
    • Albuterol | Levalbuterol | Pirbuterol
      • 2 puffs q4 to 6 hours | 2 puffs 5 minutes before exercise
      • SABA in fluid form can be used for acute asthma attacks via nebulizer (breathing machine) 
    • Works via acute bronchodilation
    • Potential side effects
      • Systemic: Tachycardia | Skeletal muscle tremor | Hypokalemia | Increased lactic acid | Headache | Hyperglycemia
      • Inhaled: Few systemic effects in otherwise healthy individuals; however, those with preexisting CVD (especially elderly) may have adverse CVD reaction  
  • Exercised-Induced Bronchoconstriction (EIB): Patients with triggering of asthmatic symptoms which can be predicted (e.g., EIB) advised to use their inhaled beta agonist approximately 10 minutes prior to exposure in order to prevent the onset of symptoms
    • Cromolyn or nedocromil can also be used for EIB

Persistent Asthma   

Step 2

Note: Before moving on to next steps, review the following: Patient’s inhaler technique | Therapy adherence | Precipitating or aggravating factors such as allergens or comorbid conditions

  • Recommendation (Preferred): Daily low-dose inhaled glucocorticoid (ICS) single agent with as needed SABA or ICS and SABA used concomitantly as needed
    • Reduces frequency of symptoms
    • Reduces the need for SABAs for symptom relief
    •  Improves the overall quality of life
    • Decreases the risk of serious exacerbations
    • Works via anti-inflammatory effect  
  • ICSs
    • Beclomethasone dipropionate | Budesonide | Flunisolide | Fluticasone propionate | Mometasone furoate | Triamcinolone acetonide        
  • Alternative strategies (not preferred)
    • Daily leukotriene receptor antagonists (LTRAs: montelukast and zafirlukast) and as needed SABA or
    • Cromolyn, or Nedocromil, or Zileuton or Theophylline, and as needed SABA
  • Patient with seasonal asthma (related to seasonal molds or pollens) should be considered as having
    • Persistent asthma during the season
    • Intermittent asthma remainder of the year

Step 3

  • Recommendation (Preferred): Daily and as needed combination low-dose ICS-formoterol
  • Alternative (not preferred)
    • Daily medium-dose ICS and as needed SABA or
    • Daily low-dose ICS-LABA, or daily low-dose ICS + LAMA (long-acting muscarinic antagonist), or daily low-dose ICS + LTRA, and as needed SABA or
    • Daily low-dose ICS + Theophylline or Zileuton, and as needed SABA

Note: For Steps 2 to 4, the guideline conditionally recommends the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥5 years of age whose asthma is controlled at the initiation, build up and maintenance phases of immunotherapy

Step 4

  • Recommendation (Preferred): Daily and as needed combination medium-dose ICS-formoterol
  • Alternative (not preferred)
    • Daily medium-dose ICS-LABA or daily medium dose ICS + LAMA and as needed SABA or
    • Daily medium-dose ICS + LTRA, or daily medium-dose ICS + Theophylline, or daily medium-dose ICS + Zileuton, and as needed SABA

 Step 5

  • Recommendation (Preferred): Daily medium-high dose ICS-LABA + LAMA and as needed SABA
  • Alternative (not preferred)
    • Daily medium-high dose ICS-LABA or daily high-dose ICS + LTRA, and as needed SABA

Step 6

  • • Daily high-dose ICS-LABA + oral systemic corticosteroids + as needed SABA
    • Use lowest dose to start on a daily or alternate-day regimen

Note: For Steps 5 and 6 consider adding Asthma Biologics (e.g. anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13)

Referral To Asthma Specialist

  • Refer to asthma specialist for consultation or comanagement for the following indications
    • Difficulty achieving or maintaining asthma control
    • Immunotherapy is being considered
    • Omalizumab is being considered
    • Patient requires step 4 care or higher
    • Exacerbation requiring hospitalization
  • Consider referral if patient requires step 3 care

Managing Acute Exacerbations Requiring Emergency Care

  • Oxygen to relieve hypoxemia in moderate or severe exacerbations
  • SABA to relieve airflow obstruction
    • Add inhaled ipratropium bromide if severe
  • Add systemic corticosteroids to decrease airway inflammation
    • If moderate or severe exacerbation or
    • If patient doesn’t respond promptly and completely to a SABA
  • If severe and not responding to above, consider
    • Adjunct treatments such as IV magnesium sulfate or heliox
  • Monitoring: Serial measurements of lung function
  • Prevent relapse
    • Referral to follow up asthma care within 1–4 weeks
    • ED asthma discharge plan that includes
      • Medication review
      • Instructions on how to increase medications or seek care if symptoms worsen
    • During follow up visits
      • Review Inhaler techniques
    • Consider ICSs

Monitoring

  • At each visit review the following
    • Asthma control
    • Asthma action plan
    • Compliance with medications
      • Stay alert once symptoms are controlled as some patients may “skip” meds, sometimes due to lack of financial resources
      • Medication technique
      • Check peak flow

Peak flow 

  • PEF (Peak Expiratory Flow) | PEFR (Peak Expiratory Flow Rate)
    • Measures the rate of air at which patient can force air out
    • “It must be stressed that peak flow meters function best as tools for ongoing monitoring, not diagnosis” (Expert Panel Report)
    • Sensitive to airway changes such as narrowing even prior to manifestation of asthmatic symptoms 
    • Use ‘personal best’ peak flow as reference value
  • ‘Normal’ value varies by gender, age and height
    • Green zone 80-100 % of personal best: OK
    • Yellow zone 50-80 % of personal best: Take quick relief medication | May need increase dose or change
    • Red zone <50 %: Call physician or go to ER

Spirometry

  • Spirometry is recommended at the time of initial assessment for diagnostic purposes, but is also used for monitoring
    • After treatment is initiated and symptoms and PEFs have stabilized
    • During periods of progressive or prolonged loss of asthma control
    • At least every 1–2 years

Schedule follow up visits

  • Every 2–6 weeks while gaining control
  • Every 1–6 months to monitor control
  • Every 3 months if step down in therapy is anticipated
    • Expert Panel recommends that the dose of ICS may be reduced about 25–50 percent every 3 months to the lowest dose possible that is required to maintain control

Treat comorbid conditions and assess vaccination status

  • Inactivated flu vaccine yearly
  • CDC also recommends
    • Pneumococcal vaccine PPSV23
      • 19 to 64 years: 1 dose
      • ≥65 years: One final dose at least five years following previous dose
    • Zoster vaccine
    • Tdap vaccine

Pregnancy

  • Check asthma control at all prenatal visits and adjust medications as needed
  • Treatment safer for both mother and fetus vs uncontrolled asthma
  • Avoid exposure to tobacco smoke

Learn More – Primary Sources:

Asthma Management Guidelines: Focused Updates 2020

Global Initiative for Asthma

CDC: Asthma Resources for Healthcare Professionals

Asthma Control Test (ACT)

American Thoracic Society: Asthma Center

NHLBI: Asthma Care Quick Reference – Diagnosing and Managing Asthma

CDC: Lung Disease including Asthma and Adult Vaccination

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Related ObG Topics:

Asthma: Diagnosis and Classification
CDC Adult Vaccination Schedule
Does Late Preterm Birth Increase Risk of Asthma?
Fish Oil During Pregnancy: Reduction of Asthma Risk in Offspring? 

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site